Navigator Medicines Inc, a new US biotech company with a focus on antibody therapeutics, has raised $100 million in a Series A financing round to develop a bispecific antibody for autoimmune diseases. Announced on 27 August, the funding round was co-led by Forbion of the Netherlands and RA Capital of the US. It will enable Navigator, a subsidiary of Sera Medicines LLC, to develop an in-licenced bispecific antibody targeting OX4OL, which is expressed on many antigen presenting cells such as dendritic cells, and tumour necrosis factor alpha (TNF-alpha), a regulator of immune cells.
